AVITA Medical ®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S.

The self-confessed late developer was in his 50s when his career hit its stride. He explains how he wound up working with Liz ...

Round positions Omeza to accelerate clinical development and scale nationwide commercialization of its FDA-cleared regenerative wound care platform SARASOTA, FL / ACCESS Newswire / April 21, 2026 ...

Texas A&M University biomedical engineering researchers have developed a treatment for chronic diabetic ulcers using ...

Published in Current Reviews in Clinical and Experimental Pharmacology, a new review finds that cannabidiol (CBD) may have strong potential in treating chronic wounds when delivered through advanced ...

1999 was a year filled with landmark movies, from the return of Star Wars and The Phantom Menace to The Matrix and Fight Club ...

Malignant cutaneous melanoma is the most invasive and metastatic type of skin cancer. Surgical resection, the conventional treatment for it, is associated with two major issues: incomplete tumor ...

Cohealyx® multi-center study interim analysis and new case data to be presented RECELL® and PermeaDerm® data reinforce a comprehensive approach to wound healing Evidence demonstrates potential to ...

VALENCIA, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced its presence at the 2026 American ...